Ira Jacobs of Pfizer's 2015 Presentation

Pfizer shares their expertise on biosimilars on the horizon

Doctor Ira Jacobs is a fellowship trained surgical oncologist who is currently Pfizer’s oncology biosimilars global medical lead. Prior to Pfizer, Doctor Jacobs worked as a medical director in oncology global development at Amgen. He led clinical development programs in breast, lung, prostate, and bone cancers. Prior to transitioning into industry, Dr. Jacobs was a staff surgical oncologist. We were …

Top 50 Pharmaceutical Companies 2014

Who are the top pharmaceutical companies in the world and what are they worth in 2014? The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with …

Challenges and Future Developments in Antibodies

As the Antibody sphere is continuously developing , we took some time out to interview senior executives speaking at the European Antibody Congress 2014 to discuss the key challenges and future developments in antibodies. Download this eBook to hear from the likes of lead representatives from Sutro Biopharma, Quality Assistance, ETH Zurich and Pfizer. The discussion circulates: What’s the most …

The Cell Culture World Congress USA is where experts like Pfizer meet to network, learn from each other, and discuss the latest cell culture strategies and technology.

Pfizer on Developing an Adaptive Manufacturing Process

Jose Gomes, Principal Scientist in charge of Culture Process Development at Pfizer, presented at last year’s Cell Culture World Congress USA. Enclosed are his presentation slides from the event, where he addresses deploying effective control strategies and optimized risk assessment with QbD to develop an adaptive manufacturing process. You can now view the recording of his presentation alongside these slides, …

clinical trials briefing, unblinding social media

Is Social Media Compromising Clinical Trials?

Pfizer’s head of Clinical Innovation for Worldwide R&D Craig Lipset, has suggested that the use of social media is ‘unblinding’ clinical trials, therefore compromising the integrity of the trial. As reported in an article by Outsourcing Pharma, through clinical trial participants discussing their treatment on social media, they are potentially coaching each other and causing a ‘false spike’ in reports …

Pfizer’s time has run out: AstraZeneca is still standing

Pfizer’s time ran out yesterday for making a formal bid to AstraZeneca, as outlined by the strict timetabling allowed for takeovers of public companies. The US drugs giant confirmed that ‘it does not intend to make an offer for AstraZeneca’. Leif Johansson, Chairman of AstraZeneca stated that in accordance with Pfizer’s confirmation to no longer pursue Astra, ‘we welcome the …

Pharma M&A Biomedical in the north

The Northern Factor and Scientific Research

Whilst the news has been dominated by Pfizer and AstraZeneca, there has been a very different story developing in the north of the UK. The Northern Health Science Alliance (NHSA) has brought together eight universities, eight NHS trusts and announced links with foreign companies, from the US and Sweden to develop new products and create ‘an internationally recognized life science …

Stem Cells Live: Current and Future Trends in Regenerative Medicine

Challenging opening comments by Greg Bonfiglio to initiate this discussion session with a bang. A series of complications have hit the industry in recent days: failure of the Athersys phase two trial, federal reimbursement for wound healing Apligraf (Organogenesis) cut. The question posed is, ‘where is the industry now and are these events predicative of the future?’ Alain Vertes, Managing …

Stem Cells Live: Celebrating the Differences, How the Biotech Culture and Big Pharma Penetrate can Help Each Other Grow the Regen Med Industry

Tim Allsopp of Neusentis, Pfizer joins host Alain Vertes for the first in a series of fireside chats focusing on Big Pharma’s role in the future of regenerative medicine. Pfizer’s strategic decision to invest in regen med stimulated the creation of Neusentis, a unit of Pfizer dedicated to this area. Dr Allsopp also spoke of Pfizer’s active identification of opportunities …

Pharma M&A Pfizer Questioned by Government

Pfizer questioned in Parliament

Pfizer’s chief Executive Ian Read is being questioned today in Parliament over Pfizer’s potential takeover bid of AstraZeneca and its commitment to the UK.   Ian Read will be subject to hostile questions in parliament today over his proposed bid for AstraZeneca. However it wont merely be Pfizer that will be questioned, AstraZeneca’s CEO Pascal Soriot and business minister Vince …